Analysts: BlackBerry’s BES Won’t Gain Traction and 3 More Research Notes to Check Out

BlackBerry (NASDAQ:BBRY): In light of its quarterly results, Macquarie downgraded Blackberry to Underperform from Neutral, as it is skeptical that it will gain traction in its BES 10 product. The price target lowered to $9.


Monster Beverage (NASDAQ:MNST): UBS said that Nielsen C-store energy data shows Monster sales were up 10.9 percent for the four week period to June 8th, versus 5.1 percent in May. The firm expects Q2 to show an improvement from Q1, and reiterates its Buy rating with a $66 price target.


Raptor Pharmaceuticals (NASDAQ:RPTP): Ladenburg has raised its price target for Raptor Pharmaceuticals to $11 from $7, after the FDA granted Procysbi orphan drug exclusivity, and the EMA recommended the granting of a marketing authorization for Procysbi on Friday. The firm maintains a Buy rating on the stock.


Orion Marine (NYSE:ORN): BB&T believes that Orion has strong opportunities to gain new business through bidding, and can raise its margins. The firm thinks that the company’s earnings can improve significantly, and it keeps a Buy rating on the shares, with a price target of $15, up from $12.


Don’t Miss: BlackBerry’s Quarterly Loss Sends Investors Running.